Elixiron reports phase 2 interim data for Alzheimer’s drug

Elixiron has announced the release of interim data from its Phase 2 clinical trial for a drug aimed at treating Alzheimer's disease. The findings provide insights into the drug's efficacy and safety profile, although specific results have not been disclosed. The company is expected to continue its research and development efforts based on these preliminary outcomes. Further details regarding the trial's methodology and participant responses are anticipated in subsequent reports.

Read More